Trajectories of injectable cancer drug costs after launch in the United States

Journal of Clinical Oncology

Volumn 36, Issue 4, 2018, Pages 319-325

  Gordon, Noa ^a,b   Stemmer, Salomon M ^a,c   Greenberg, Dan ^b   Goldstein, Daniel A ^a,d  

^a RABIN MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CABAZITAXEL; CETUXIMAB; CLOFARABINE; DENOSUMAB; ERIBULIN; IPILIMUMAB; IXABEPILONE; NELARABINE; OFATUMUMAB; PACLITAXEL; PANITUMUMAB; PEMETREXED; PERTUZUMAB; PRALATREXATE; RITUXIMAB; TEMSIROLIMUS; TRASTUZUMAB; VINCRISTINE;

ARTICLE; DRUG COST; DRUG MARKETING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAID; MEDICARE; PATENT; PRIORITY JOURNAL; UNITED STATES; COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG INDUSTRY; ECONOMICS; INJECTION; TIME FACTOR; TRENDS;

ANTINEOPLASTIC AGENTS; COMMERCE; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; HUMANS; INJECTIONS; MEDICARE PART B; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85041134053     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.72.2124     Document Type: Article

References (27)

1. Ramsey S, Blough D, Kirchhoff A, et al: Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32:1143-1152, 2013
2. Kent EE, Forsythe LP, Yabroff KR, et al: Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer 119: 3710-3717, 2013
3. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
4. Ramsey SD, Bansal A, Fedorenko CR, et al: Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34:980-986, 2016
5. Drummond M, Sorenson C: Can NICE be nicer? In a world of budget constraints there are no easy solutions. Value Health 12:634-636, 2009
6. Ubel PA, DeKay ML, Baron J, et al: Cost-effectiveness analysis in a setting of budget constraints: Is it equitable? N Engl J Med 334:1174-1177, 1996
7. Bach PB: Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
8. Howard DH, Bach PB, Berndt ER, et al: Pricing in the market for anticancer drugs. J Econ Perspect 29:139-162, 2015
9. Druker BJ, Guilhot F, O’Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006
10. Experts in Chronic Myeloid Leukemia: The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood 121:4439-4442, 2013
11. Saltz LB: The value of considering cost, and the cost of not considering value. J Clin Oncol 34: 659-660, 2016
12. Bennette CS, Richards C, Sullivan SD, et al: Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff (Millwood) 35:805-812, 2016
13. Dusetzina SB: Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000-2014. JAMA Oncol 2: 960-961, 2016
14. Curtiss FR, Lettrich P, Fairman KA: What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm 16: 492-501, 2010
15. Sheingold S, Marchetti-Bowick E, Nguyen N, et al: Medicare Part B drugs: Pricing and incentives. ASPE https://aspe.hhs.gov/system/files/pdf/187581/PartBDrug.pdf, 2016
16. CenterWatch: 2016 FDA approved drugs. http://www.centerwatch.com/drug-information/fda-approveddrugs/year/2016
17. Goldstein DA, Chen Q, Ayer T, et al: First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A United States-based cost-effectiveness analysis. J Clin Oncol 33: 1112-1118, 2015
18. Centers for Medicare and Medicaid Services: Medicare Part B drug average sales price: Manufacturer reporting of average sales price (ASP) data. https://www.cms.gov/Medicare/Medicare-Fee-for-ServicePart-B-Drugs/McrPartBDrugAvgSalesPrice/index.html
19. US Department of Labor: Bureau of Labor Statistics: CPI inflation calculator. https://www.bls.gov/data/inflation_calculator.htm
20. US Food and Drug Administration: Drugs@ FDA: FDA approved drug products. http://www.fda.gov/drugsatfda
21. TruvenHealthAnalytics:Compendiatransparency. http://micromedex.com/compendia
22. Centers for Medicare and Medicaid Services: 2015 Medicare drug spending dashboard. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-PrescriptionDrugs/2015Medicare.html
23. Outterson K, Kesselheim AS: How Medicare could get better prices on prescription drugs. Health Aff (Millwood) 28:w832-w841, 2009
24. Kantarjian H, Rajkumar SV: Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc 90:500-504, 2015
25. Mailankody S, Prasad V: Implications of proposed Medicare reforms to counteract high cancer drug prices. JAMA 316:271-272, 2016
26. Savage P, Mahmoud S, Patel Y, et al: Cancer drugs: An international comparison of postlicensing price inflation. J Oncol Pract 13:e538-e542, 2017
27. Kesselheim AS, Avorn J, Sarpatwari A: The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA 316:858-871, 2016